High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

NCT01704716 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3300

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Vincristine
DRUG: Aldesleukin
DRUG: ch14.18/CHO
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: G-CSF
DRUG: Busulfan
DRUG: Melphalan

Sponsor

St. Anna Kinderkrebsforschung